Company: BNBX
Filing Date: 2025-10-30
Form Type: S-1
Source: 0001104659-25-103871
Chunk: 26

Company: BNB PLUS CORP.
Filing Date: 2025-10-30
Form: S-1
Chunk 26
---
 (or announce any offer, sale, grant or any option to purchase or other disposition) any shares of Common Stock, at an effective price per share less than the exercise price of the May 2024 Series A Warrants then in effect (the “Fundamental Transaction Price Reset Mechanism” and, each of the Fundamental Transaction Price Reset Mechanism and the Reverse Split Price Reset Mechanism, a “Price Reset Mechanism”). The number of shares issuable upon exercise after the Fundamental Price Reset Mechanism will be proportionately adjusted such that the aggregate exercise price will remain unchanged.

<div align='center'>13</div>

On October 30, 2024, the Company and certain holders of the May 2024 Series A Warrants entered into an amendment to such holders’ May 2024 Series A Warrants (the “Warrant Amendment”), pursuant to which the Fundamental Transaction Price Reset Mechanism became subject to a floor. All of the remaining outstanding May 2024 Series A Warrants have reached their floor and will not be subject to further adjustment due to the Fundamental Transaction Price Reset Mechanism.

The Price Reset Mechanisms of the May 2024 Series A Warrants were triggered by the October 2024 Offering (as defined below), the 1-for-50 reverse stock split of our Common Stock effected on March 14, 2025 (the “March 2025 Reverse Split”) and the June 2025 Reverse Split, and therefore the number of shares of Common Stock issuable upon exercise of the outstanding May 2024 Series A Warrants has been adjusted to 3,091,049 and the exercise price of the May 2024 Series A Warrants has been adjusted to $5.13 per share. As of September 30, 2025, all of the remaining May 2024 Series B Warrants expired and there were none outstanding.

If any of the above provisions in the May 2024 Series A Warrants are further utilized, our stockholders may suffer substantial dilution.

Stockholders may suffer substantial dilution if certain provisions in the Series E Warrants, Advisory Warrants, Placement Agent Warrants or Consultant Warrants are utilized.

Pursuant to the closing of the Private Placement, the Series E Warrants, Advisory Warrants and Consultant Warrants were issued. Additionally, in connection with the Private Placement, the Company sold to the Placement Agent the Placement Agent Warrants to purchase shares of our Common Stock equal to 5.0% of our Common Stock sold in the Private